Articles by Abby Proch

  1. Calidi's Study Aims To Have An Oncolytic Virus Outsmart The Immune System 10/2/2026

    Calidi’s Eric Poma, Ph.D., explains how CLD-401 could evade immune clearance — and how the biotech is designing Phase 1 to prove safety and efficacy fast.

  2. New Imaging Approach Could Improve IPF Trial Design 10/1/2026

    AI-powered quantitative CT could help sponsors detect treatment effects earlier, strengthen IPF trial endpoints, and make better go/no-go decisions.

  3. Examining The Potential Of P-tau217 To Provide Earlier Diagnosis Of Alzheimer's 9/25/2026

    P-tau217 blood tests could accelerate Alzheimer’s diagnosis. Lilly’s Nino Sireci, MD, MSc, explains the research, evidence thus far, potential clinical use, and next steps.

  4. How VNS-REHAB Aims To Improve Stroke Recovery After Patients Have Plateaued 9/22/2026

    Learn how a stroke trial standardized intensive therapy, sustained patient adherence, and exposed access barriers after FDA approval.

  5. Repurposing Three FDA-Approved Drugs For A New Stroke Recovery Strategy 9/17/2026

    When three drugs become one — the polypharmacology strategy, 505(b)(2) pathway, and objective endpoints Nuero-Innovators is relying on to bring new hope to stroke patients.

  6. Coalition Takes Guesswork Out Of Charcot-Marie-Tooth Disease Research With New Guidance 9/16/2026

    A new Charcot-Marie-Tooth guidance introduces practical recommendations to help sponsors design clearer, more patient-centered, regulator-ready trials.

  7. Dose Escalation, Combination Strategy Keep Aprea Ahead In Its Oncology Trials 9/2/2026

    Aprea’s Gene Kennedy explains how smart dose escalation, next-gen sequencing, and combination planning are helping the company advance its oncology trial for multiple solid tumor types.

  8. How A $96M Gift Is Transforming Pediatric Brain Cancer Clinical Trial Infrastructure 9/1/2026

    By pairing donor priorities with research needs at Children's National, Milken Institute SPARC is turning philanthropy into faster trials, stronger infrastructure, and long-term care goals.

  9. Planning A Global Clinical Trial With The Right Sites, Not The Most Sites 8/27/2026

    Less is more for Yi Larson and the team at Excursion Therapeutics, which opted to build right site network — not the largest one — for its Phase 2 trial.

  10. Turning A Historically Limited Modality Into A Respiratory Drug Opportunity 8/26/2026

    How can sponsors revive a promising modality with known safety limits? Vast Therapeutics CEO Nate Stasko, Ph.D., explains how ALX1 is reshaping nitric oxide delivery.